# SPECIALTY GUIDELINE MANAGEMENT

# LENVIMA (lenvatinib)

#### **POLICY**

#### I. INDICATIONS

The indications below including FDA-approved indications and compendial uses are considered a covered benefit provided that all the approval criteria are met and the member has no exclusions to the prescribed therapy.

## A. FDA-Approved Indications

- 1. Lenvima is indicated for the treatment of patients with locally recurrent or metastatic, progressive, radioactive iodine-refractory differentiated thyroid cancer (DTC).
- 2. Lenvima is indicated in combination with everolimus, for the treatment of patients with advanced renal cell carcinoma (RCC) following one prior anti-angiogenic therapy.
- 3. Lenvima is indicated for the first-line treatment of patients with unresectable hepatocellular carcinoma (HCC).

# B. Compendial Uses

Medullary, follicular, Hurthle cell or papillary thyroid carcinoma

All other indications are considered experimental/investigational and are not a covered benefit.

#### II. CRITERIA FOR INITIAL APPROVAL

# A. Thyroid carcinoma

Authorization of 12 months may be granted for the treatment of medullary, follicular, Hurthle cell, or papillary thyroid carcinoma

### B. Renal Cell Carcinoma

Authorization of 12 months may be granted for the treatment of relapsed or advanced renal cell carcinoma.

### C. Hepatocellular Carcinoma

Authorization of 12 months may be granted for the treatment of unresectable hepatocellular carcinoma.

## **III. CONTINUATION OF THERAPY**

All members (including new members) requesting authorization for continuation of therapy must meet all initial authorization criteria.

## IV. REFERENCES

- 1. Lenvima [package insert]. Woodcliff Lake, NJ: Eisai Inc.; August 2018.
- 2. The NCCN Drugs & Biologics Compendium 2018 National Comprehensive Cancer Network, Inc. http://www.nccn.org. Accessed November 5, 2018.
- 3. National Comprehensive Cancer Network. NCCN Clinical Practice Guidelines in Oncology Thyroid Carcinoma (Version 1.2018). http://www.nccn.org. Accessed November 5, 2018.

Lenvima 1865-A SGM P2019

© 2019 CVS Caremark. All rights reserved.

This document contains confidential and proprietary information of CVS Caremark and cannot be reproduced, distributed or printed without written permission from CVS Caremark. This document contains prescription brand name drugs that are trademarks or registered trademarks of pharmaceutical manufacturers that are not affiliated with CVS Caremark.



Reference number	
1865-A	

National Comprehensive Cancer Network. NCCN Clinical Practice Guidelines in Oncology Kidney Cancer (Version 2.2019). http://www.nccn.org. Accessed November 5, 2018.

Lenvima 1865-A SGM P2019

© 2019 CVS Caremark. All rights reserved.